Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, Ltd., filed a Form 4 on November 19, 2026, disclosing the sale of common shares on November 18, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • First tranche: 11,715 common shares disposed of at a weighted average price of $28.2837, with individual sale prices ranging from $27.7927 to $28.7900.
  • Second tranche: 3,285 common shares disposed of at a weighted average price of $29.0951, with individual sale prices ranging from $28.8300 to $29.2950.
  • Post-transaction ownership: Webster directly held 430,215 common shares following both sales.
  • Trading plan: Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026, as noted in the filing's explanation of responses.
  • Reporting person roles: Webster is identified in the filing as both a Director and the President and Chief Executive Officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS).

Webster's November 18 Share Sales at Kestra Medical Technologies

According to the Form 4 filed with the SEC, Brian Daniel Webster sold common shares of Kestra Medical Technologies, Ltd. in two separate transactions on November 18, 2026. The first transaction covered 11,715 shares at a weighted average price of $28.2837, reducing his directly held position from 445,215 shares to 433,500 shares. The filing notes that the actual sale prices in this tranche ranged from $27.7927 to $28.7900 per share.

The second transaction covered 3,285 shares at a weighted average price of $29.0951, further reducing his direct holdings to 430,215 common shares. Sale prices in this tranche ranged from $28.8300 to $29.2950, according to the filing. Both weighted average prices are as reported in the filing, and the filing states that detailed per-share information is available upon request to the issuer, any security holder, or the SEC staff.

Kestra Medical Technologies is the issuer of the common shares covered by this filing. The filing identifies both transactions as disposal (D) transactions under transaction code S, meaning open-market sales. Webster's address of record in the filing is 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033, which corresponds to the company's location. The filing was signed by Webster on November 19, 2026.

What Was Disclosed

The filing disclosed two open-market sales of Kestra Medical Technologies common shares by CEO Brian Daniel Webster on November 18, 2026, totaling 11,715 and 3,285 shares in separate tranches, executed under a Rule 10b5-1 plan adopted July 21, 2026, leaving Webster with 430,215 directly held shares.